BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12151195)

  • 1. Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):323-6. PubMed ID: 12151195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
    Davies TA; Kelly LM; Hoellman DB; Ednie LM; Clark CL; Bajaksouzian S; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Mar; 44(3):633-9. PubMed ID: 10681330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.
    Wise R; Andrews JM
    J Antimicrob Chemother; 1999 Nov; 44(5):679-88. PubMed ID: 10552986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria.
    Fuchs PC; Barry AL; Brown SD
    Diagn Microbiol Infect Dis; 2000 Dec; 38(4):243-53. PubMed ID: 11146251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model.
    Portnoy YA; Vostrov SN; Lubenko IY; Zinner SH; Firsov AA
    Int J Antimicrob Agents; 2002 Sep; 20(3):201-5. PubMed ID: 12385699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group.
    Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 2000 Jul; 37(3):195-201. PubMed ID: 10904193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.
    Fuentes F; Giménez MJ; Marco F; Alou L; Aguilar L; Prieto J
    Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):137-9. PubMed ID: 10746503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.
    Marchese A; Debbia EA; Schito GC
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():11-5. PubMed ID: 10997594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens.
    Rittenhouse S; McCloskey L; Broskey J; Niconovich N; Jakielaszek C; Poupard J; Coleman K
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():23-7. PubMed ID: 10824028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.
    Joyanes P; Pascual A; Giménez MJ; García I; Aguilar L; Perea E
    Chemotherapy; 2001 Dec; 47(6):409-14. PubMed ID: 11786655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
    Tanaka M; Tunoe H; Mochida O; Kanayama A; Saika T; Kobayashi I; Naito S
    Diagn Microbiol Infect Dis; 2000 Oct; 38(2):109-13. PubMed ID: 11035242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone.
    Jones RN; Erwin ME; Biedenbach DJ; Johnson DM; Pfaller MA
    Diagn Microbiol Infect Dis; 1999 Nov; 35(3):227-34. PubMed ID: 10626134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.
    García-Garrote F; Cercenado E; Martín-Pedroviejo J; Cuevas O; Bouza E
    J Antimicrob Chemother; 2001 May; 47(5):681-4. PubMed ID: 11328784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
    Lopez H; Stepanik D; Vilches V; Scarano S; Sarachian B; Mikaelian G; Finlay J; Sucari A
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
    Jones RN; Biedenbach DJ; Erwin ME; Beach ML; Pfaller MA
    J Clin Microbiol; 1999 Jun; 37(6):1999-2002. PubMed ID: 10325362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.
    Balkhy HH; Memish ZA; Shibl A; Elbashier A; Osoba A
    East Mediterr Health J; 2005; 11(1-2):36-44. PubMed ID: 16532669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
    García-Olmos M; Parra A; García-Calvo G; Ponte C; Giménez MJ; Aguilar L; Soriano F
    Int J Antimicrob Agents; 2003 Jun; 21(6):568-73. PubMed ID: 12791471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods.
    Jones RN; Deshpande LM; Erwin ME; Barrett MS; Beach ML
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():67-70. PubMed ID: 10824035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.